Paper25614146
Camelid nanobodies: killing two birds with one stone.
Desmyter A and 3 others. Curr Opin Struct Biol, 2015. Cited by 91 papers, by iCite.
Cite this record
ConductScience Library. Camelid nanobodies: killing two birds with one stone. Papers, record 25614146. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25614146
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Camelids, New World | Major topic |
| Proteins | Major topic |
| Single-Domain Antibodies | Major topic |
| Animals | |
| Crystallization | |
| Humans | |
| Models, Molecular | |
| Protein Conformation | |
| Protein Stability |
Source PubMed
Cited by64
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42352241 | Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352241 | PubMed |
| 42121126 | Affinity enhancement of an anti-VEGF humanized nanobody as a superior candidate to bevacizumab: integrative in silico and in vitro studies. | BMC Biotechnol | 2026 | https://conductscience.org/library/papers/42121126 | PubMed |
| 41953754 | Generation of Nano-Antibodies Targeting the SNMP1 Membrane Receptor of Spodoptera littoralis Using Extracellular Vesicles. | J Extracell Biol | 2026 | https://conductscience.org/library/papers/41953754 | PubMed |
| 41704535 | VNAR: shark single-domain antibodies for the new era of medical biotechnology. | Front Immunol | 2025 | https://conductscience.org/library/papers/41704535 | PubMed |
| 41324409 | Single mutations to tyrosine or glutamate improve the crystallizability and crystal diffraction properties of a flexible two-domain protein. | Acta Crystallogr F Struct Biol Commun | 2026 | https://conductscience.org/library/papers/41324409 | PubMed |
| 41141363 | Optimization of the VSV-G backbone for amino terminal fusion with nanobodies allowing its specific retargeting to HER2 receptors. | Mol Ther Oncol | 2025 | https://conductscience.org/library/papers/41141363 | PubMed |
| 40634277 | Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40634277 | PubMed |
| 40474190 | A phage-displayed nanobody-based competitive immunoassay for the detection of African swine fever virus antibodies. | Virol J | 2025 | https://conductscience.org/library/papers/40474190 | PubMed |
| 40427736 | Nanobodies: From Discovery to AI-Driven Design. | Biology (Basel) | 2025 | https://conductscience.org/library/papers/40427736 | PubMed |
| 40410172 | Emerging biosensors integrated with microfluidic devices: a promising analytical tool for on-site detection of mycotoxins. | NPJ Sci Food | 2025 | https://conductscience.org/library/papers/40410172 | PubMed |
| 40275270 | Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40275270 | PubMed |
| 38771414 | Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons. | World J Microbiol Biotechnol | 2024 | https://conductscience.org/library/papers/38771414 | PubMed |
| 38687705 | An optimized approach to study nanoscale sarcomere structure utilizing super-resolution microscopy with nanobodies. | PLoS One | 2024 | https://conductscience.org/library/papers/38687705 | PubMed |
| 38512665 | Recombinant Production and Characterization of VHHs/Nanobodies Targeting Tau to Block Fibrillar Assembly. | Methods Mol Biol | 2024 | https://conductscience.org/library/papers/38512665 | PubMed |
| 38350843 | Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries. | BMC Infect Dis | 2024 | https://conductscience.org/library/papers/38350843 | PubMed |
| 38341572 | Development and characterization of a novel nanobody with SRMV neutralizing activity. | Microb Cell Fact | 2024 | https://conductscience.org/library/papers/38341572 | PubMed |
| 37533864 | A comparison of the binding sites of antibodies and single-domain antibodies. | Front Immunol | 2023 | https://conductscience.org/library/papers/37533864 | PubMed |
| 37328468 | Structure and antigenicity of divergent Henipavirus fusion glycoproteins. | Nat Commun | 2023 | https://conductscience.org/library/papers/37328468 | PubMed |
| 35646824 | Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools. | Front Chem | 2022 | https://conductscience.org/library/papers/35646824 | PubMed |
| 35157279 | Humanization of Camelid Single-Domain Antibodies. | Methods Mol Biol | 2022 | https://conductscience.org/library/papers/35157279 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25614146
GET https://conductscience.org/api/papers/v1/25614146/cited_by?page=2